The UK's emerging landscape of mind-altering substances is witnessing a remarkable shift, moving far outside the traditional concentration on psilocybin and lysergic acid diethylamide. Attention is now directed on newer compounds, like dimethyltryptamine, CBG which is showing potential wellness properties, and a range of novel substances currently